InspireMD reported Q2 2026 revenue of $1.8 million, flat year-over-year, driven by a 21% international growth offset by U.S. sales declines due to a voluntary recall of the CGuard Prime 135 cm delivery system. The company incurred a net loss of $14.3 million ($0.17 per share), including $612,000 in inventory impairment and $734,000 in customer credits related to the recall. U.S. revenue turned negative at $(351,000). Following the quarter, InspireMD initiated cost-saving actions expected to yield approximately $9 million in annual savings. The company appointed Kathleen Kennedy as SVP of Global Sales and Marketing ahead of a planned U.S. re-launch. Clinical updates included 100% acute device success in the CGUARDIANS II trial for TCAR procedures and enrollment commencement in the CGUARDIANS III pivotal trial. InspireMD develops medical devices, specifically carotid stent systems, to prevent stroke.
